Key Drivers
- Strong cash generation
- Rising leverage
- Intangible asset risk
AIAI Summary
Sanofi's strong cash flow and dividend support make it attractive near oversold levels, but investors should treat it as an execution-dependent growth transition: upside hinges on sustaining Dupixent while proving pipeline replacements and integrating the Cheplapharm divestiture without worsening concentration risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash generation
- •Rising leverage
- •Intangible asset risk
Sanofi remains highly profitable with strong cash flow and dividend coverage, but weakening liquidity, rising debt, substantial intangible-asset exposure, and richer valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Oversold momentum
SNY remains bearish over the last month, with support at $42.40–$42.50 and a possible oversold bounce, but a break below support could extend losses unless it reclaims $43.30–$43.50 resistance.
Decline accelerated after peaking at $46.02 on 2026-08-25
Sentiment & News
Key News Insights:
- •Dupixent momentum
- •R&D reset
- •Vaccine weakness
Sanofi's improving growth drivers, R&D reset, and attractive valuation are offset by pipeline and vaccine weakness, supporting a cautious outlook.
The news is modestly positive for Sanofi, but consensus “Hold” sentiment suggests limited near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings